CD47 and neoplasm: This is consistent with recent data obtained from the ID8 ovarian carcinoma model in which gene therapy vectors engineered to express 3TSR (i.e., CD36-activating TSP-1 fragment), together with a CD47-binding peptide, were shown to inhibit primary tumor growth and development of secondary lesions [42].